CoChat

Current strategies for treatment of relapsed/refractory multiple myeloma

Laubach, Jacob P, Voorhees, Peter M, Hassoun, Hani, Jakubowiak, Andrzej, Lonial, Sagar, Richardson, Paul G · 2014 · Expert Review of Hematology
Cited by 67

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

In spite of significant advances in the management of multiple myeloma (MM), the disease remains incurable and nearly all patients ultimately relapse and require salvage chemotherapy. As such, relapsed and relapsed-refractory MM remains a critical area of research pertaining to biological mechanisms of progression and chemotherapy resistance, as well as to the development of new pharmacologic agents and immunologic approaches for the disease. The immunomodulatory agents and proteasome inhibitors represent the cornerstone of treatment in this setting, with combination regimens incorporating these drugs demonstrating encouraging rates and duration of response, including the newer agents, pomalidomide and carfilzomib. In addition, novel drug classes have shown promising activity in RR MM, including the orally-administered proteasome inhibitors ixazomib and oprozomib; monoclonal antibodies such as the anti-CS1 monoclonal antibody elotuzumab and anti-CD38 monoclonal antibody daratumumab; and histone deacetylase inhibitors such as panobinostat and rocilinostat.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/17474086.2014.882764

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 67

Metadata

Authors
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A., Lonial, S., & Richardson, P. G.
Venue
Expert Review of Hematology
Published
2014-01-29
Volume
7
Issue
1
Pages
97-111
ISSN
  • 1747-4086 (ISSN-L)
  • 1747-4094
OpenAlex
W2158608759
Cited by
67
References
19
FWCI
8.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current strategies for treatment of relapsed/refractory multiple myeloma. https://app.cochat.ai/papers/10.1586/17474086.2014.882764
The paper
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A., Lonial, S., & Richardson, P. G. (2014). Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Review of Hematology. https://doi.org/10.1586/17474086.2014.882764

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.